JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

SURGICAL GASTROENTEROLOGY

    1. North-West State Medical University named after I. I. Mechnikov (St. Petersburg, Russian Federation)

    Keywords:postoperative protein-energy insufficiency,enteral insufficiency,elderly and old patients

    Abstract:The study performed showed that elderly and old patient surviving ulcer disease surgical treatment suffer one of the most common complications (31 % of cases) in the remote postoperative period, i. e. protein-energy insufficiency, occurring on the background of the enteral insufficiency development and progress. Hypertrophy and hyperplasia of the superficial-foveolar epithelium of the small intestine (in 62.15 % and 71.8 % respectively) arising probably as a result of inadequate adaptive-compensatory reaction to the disorder of neurohumoral regulation of the alimentary tract activity is rather often precedes the development of protein-energy insufficiency in postoperative period in elderly patients. Formation of enteral insufficiency and protein-energy insufficiency on its background is connected with the depression of functional competence of the atrophically changed small intestinal mucosa, manifested in secretory disorders and disturbances of its absorptive function.

      1. Барановский А. Ю., Логунов К. В., Протопопова О. Б. Болезни оперированного желудка (профилактика и лечение: совместная позиция терапевта и хирурга): Руковод. для врачей. - СПб.: Издат. дом СПбМАПО, 2010. - 382 с.
      2. Возрастная гастроэнтерология. Том 3: Хирургическая гастроэнтерология пожилого и старческого возраста (избранные разделы)/ под ред. Л. Н. Костюченко. - М., 2009. - 280 с.
      3. Костюченко Л. Н., Кузьмина Т. Н. Синдром пострезекционной дистрофии у больных пожилого и старческого возраста: нутритивная коррекция // Клин. геронтол. 2011. № 1. С. 32-34.
      4. Красильников Д. М., Хайруллин И. И., Фаррахов А. З. Ранние послеоперационные осложнения у больных язвенной болезнью желудка и двенадцатиперстной кишки. Казань: Медицина. 2005. - 152 с.
      5. Свиридов С. В., Розумейко В. П., Алиева Т. У., Федоров С. В., Шодиев И. А. Предоперационная оценка белково-энергетической недостаточности и иммунного статуса у хирургических больных// Трудный пациент. 2010. № 11. С. 47-51.
      6. Фролова Е. В., Корыстина Е. М. Основные характеристики пожилых пациентов с белково-энергетической недостаточностью и риском ее развития // Российский семейный врач. Т. 15. 2011. № 4.
      7. Савельев В. С., Лубянский В. Г., Петухов В. А. Дисметаболические последствия синдрома кишечной недостаточности в абдоминальной хирургии // Анналы хирургии. - 2005. - № 6. - 39-42 с.
      8. Костюченко Л. Н., Кузьмина Т. Н. Синдром пострезекционной дистрофии у больных пожилого и старческого возраста: нутритивная коррекция // Клин. геронтол. - 2011. - № 1. - С. 32-34.
      9. Locher J. L., Roth D. L., Ritchie C. S. et al. Body mass index, weight loss, and mortality in community-dwelling older adults // J. Gerontol. A. Biol. Sci. Med. Sci. 2007. 62. P. 1389-1392.
      10. Newman A. B., Yanez D., Harris T. et al. Weight change in old age and its association with mortality // J. Am. Geriatr. Soc. 2001. 49. P. 1309-1318.
      11. Парфенов А. И. Энтерология. М.: Триада-Х, 2002. - 744 с.
     


    Full text is published :
    Baranovsky A.Yu., Khmelnitskaya N.M., Protopopova O.V. MORPHOFUNCTIONAL STATE OF SMALL INTESTINE PROXIMAL PART AT THE FORMATION OF PROTEIN-ENERGY INSUFFICIENCY IN ELDERLY AND OLD PATIENTS AFTER STOMACH SURGICAL TREATMENT. Experimental and Clinical Gastroenterology Journal. 2017;146(10):54-60
    Read & Download full text

    1. Federal State Budgetary Institution «V. A. Almazov Federal North-West Medical Research Centre» of the Ministry of Health of the Russian Federation (St. Petersburg, Russian Federation)
    2. Pavlov First Saint Petersburg State Medical University of the Russian Federation (St. Petersburg, Russian Federation)

    Keywords:Non-alcoholic fatty liver disease,non-alcoholic steatosis of the liver,liver cirrhosis,type 2 diabetes mellitus,insulin resistance,hyperinsulinemia,obesity,bariatric surgery,glucagon-like peptide-1,ghrelin

    Abstract:Patients with a metabolic syndrome in combination with non-alcoholic fatty liver disease (NAFLD) have an increased risk of cardiovascular complications and mortality. The review presents epidemiology, the pathogenesis of non-alcoholic fatty liver disease, the possibilities of bariatric surgery in treatment of this disease, and current understanding of the hepatotropic effects of the most studied gastrointestinal hormones: glucagon-like peptide-1 and ghrelin, which profile changes under the influence of bariatric operations.

      1. Ивашкин В. Т., Маевская М. В. Липотоксичность и другие метаболические нарушении при ожирении. Российский журнал гастроэнтерологии, гепатологии и колопроктологии, 2010, том 1, С. 4-13
      2. Brunt E. M. Nonalcoholic steatohepatiatis. Semin Liver Dis, 2004, Vol.24, pp.3-20
      3. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome // Diabetes. - 2001. - Vol. 50. - P. 1844-50
      4. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis, 2004, vol.8, no.3, pp.501-519
      5. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug, vol.34, no.3, pp.274-85.
      6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012 Jun, vol.142, no.7, pp.1592-609.
      7. Bedogni G., Miglioli L., Masutti F., Tiribelli C. Prevalence and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology, 2005, vol.42, pp.44-52
      8. Agopian V. G., Kaldas F. M., Hong J. C., Whittaker M., Holt C., Rana A., Zarrinpar A., Petrowsky H., Farmer D., Yersiz H., Xia V., Hiatt J. R., Busuttil R. W. Liver transplantation for non-alcoholic steatohepatitis: the new epidemic. Ann. Surg, 2012, vol.256, pp.624-633.
      9. Clemente MG, Mandato C, Poeta M, Vajro P. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol. 2016 Sep 28, vol.22, no.36, pp.8078-93.
      10. Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis, 2010, vol.42, no.5, pp.320-330
      11. Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, MagnusonTH. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res, 2005, vol.13, no.7, pp.1180-1186.
      12. Драпкина О. М., Ивашкин В. Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования наблюдения DIREGL 01903). Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2014, т. 24, № 4, с. 32-38.
      13. Ивашкин В. Т., Драпкина О. М., Маев И. В., Трухманов А. С., Блинов Д. В., Пальгова Л. К., Цуканов В. В., Ушакова Т. И. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2015, № 6, с. 31-41.
      14. Lazo M, Clark JM, editors. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Seminars in liver disease, 2008, vol.28, no.4, pp. 339-350.
      15. Festi D. et al., 2004; Leite N. C. et al., 2009; Smith B. W. et al., 2011.
      16. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology, 1999, vol.116, no.1413, pp.9-13.
      17. Misra Vijay Laxmi, Khashab Mouen, Chalasani Naga. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep, 2009, no.1, pp.50-55.
      18. Belentani S. et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med, 2000, no.132, pp.112-117.
      19. Musso G., Gambino et al. R. Non-alcogolic fatty liver disease from pathogenesis to management: an update. Obes. Rev., 2010, vol.11, pp. 430-445.
      20. Ивашкин В. Т. Болезни печени и желчевыводящих путей; Руководство для врачей - 2-е изд. - М.: М-Вести, 2005 - С. 205.
      21. Вольфгант Герок-Хуберт Е. Блюм. Заболевания печени и желчевыделительной системы/Пер. с нем.; под общей редакцией Ивашкина В. Т., Шептулина А. А. - М.: МЕДпресс-информ. - 2009. - 200 с.
      22. Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg, 2005, vol.242, no.4, pp.610-617.
      23. Л. И. Буторова. Неалкогольная жировая болезнь печени как проявление метаболического синдрома: эпидемиология, патогенез, особенности клинического проявления, принципы диагностики, современные возможности лечения. Пособие для врачей. М.: Медиа медика. - 2012. - 54 с.
      24. Garc M. C. Non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology, 2001, no.24, pp. 395-402.
      25. Полунина Т. Е. Неалкогольная жировая болезнь печени. Алгоритм диагностики и лечебной тактики. Пособие для врачей общей практики, терапевтов и гастроэнтерологов. Учебно-методическое пособие. М.: Медиа медика. - 2014. - 32 c.
      26. Российское общество по изучению печени Методические рекомендации для врачей Диагностика и лечение неалкогольной жировой болезни печени. Под редакцией академика РАН, профессора В. Т. Ивашкина. - Москва. - М.: Медиа медика. - 2015.
      27. Attar BM, Van Thiel DH. Current concepts and management approaches in nonalcoholic fatty liver disease. ScientificWorldJournal, 2013, vol.5, no.3, pp.15-18.
      28. Franz MJ, VanWormer JJ, Craiin AL, Boucher JL, Histon T, Caplan W, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc, 2007, vol.107, no.10, pp.1755-67.
      29. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA, 2004, vol.292, no.14, pp.1724-1737.
      30. Mottin CC, Moretto M, Padoin AV, et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obes Surg, 2005, vol.15, no.6, pp.788-793.
      31. Ranlov I, Hardt E. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion, 1990, vol.47, no.3, pp.208-14.
      32. Keshishian A, Zahriya K, Willes EB. Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months. Obes Surg, 2005, vol.15no.7, pp.418-423.
      33. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Detabase Syst Rev, 2010, vol.20, no.1, pp.47-57.
      34. Rabl C 1, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis, 2012 Feb, vol.32, no.1, pp.80-91.
      35. Alli V, Rogers AM. Gastric Bypass and Influence on Improvement of NAFLD.Curr Gastroenterol Rep, 2017 Jun, vol.19, no.6, pp.25.
      36. Клинические рекомендации EASL-EASD-EASO по диагностике и лечению неалкогольной жировой болезни печени. Journal of Hepatology 2016 том 64, с. 1388-1402.
      37. Sasaki A, Nitta H, Otsuka K, Umemura A, Baba S, Obuchi T, Wakabayashi G. Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments. Front Endocrinol,2014 Oct 27, vol.5, pp.164.
      38. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Detabase Syst Rev, 2010, vol.20, no.1, pp.45-56.
      39. Rabl C, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis, 2012 Feb, vol.32, no.1, pp.80-91.
      40. Hassanian M, Al-Mulhim A, Al-Sabhan A, Al-Amro S, Bamehriz F, Abdo A, Al Khalidi H, Aldoheyan TA. The effect of bariatric surgeries on nonalcoholic fatty liver disease. Saudi J Gastroenterol, 2014 Sep-Oct, vol.20, no.5, pp.270-278.
      41. Nascimento TM, Alves-Júnior A, Nunes MA, de Freitas TR, da Silva MA, Alves MR. Comparison of hepatic profile in pre and postoperative of bariatric surgery: private vs public network. Arq Bras Cir Dig, 2015, vol.28, no.4, pp.274-277.
      42. Sasaki A, Nitta H, Otsuka K, Umemura A, Baba S, Obuchi T, Wakabayashi G. Bariatric surgery and non-alcoholic Fatty liver disease: current andpotential future treatments. Front Endocrinol (Lausanne), 2014 Oct 27, vol.5, pp.164.
      43. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology, 2005, vol.128 no.7, pp.1898-1906.
      44. Hocking MP, Dierson MC, Alexander RN et al. Late hepatic histology after jejunoileal bypass for morbid obesity. Am J Surg, 1981, vol.141, no.14, pp.159-63.
      45. Kleiner DE, Berk PD, Hsu JY, Courcoulas AP, Flum D, Khandelwal S, et al. Hepatic pathology among patients without known liver disease undergoing assessment of bariatric surgery (LABS) study. Semin Liver Dis, 2014, vol.34, no.6, pp.98-107.
      46. Klein S, Mittendorfer B, Eagon JC, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology, 2006, vol.130, no.6, pp.1564-1572.
      47. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Detabase Syst Rev, 2010, vol.20, no.1, pp.56-59.
      48. Vyberg M, Rain V, Andersen B. Pattern of progression in liver injury following jejunoileal bypass for morbid obesity. Liver, 1987, vol.7, pp.271-6.
      49. Sgambato D, Cotticelli G, de Sio I, Funaro A, Del Prete A, de Sio C, Romano L, Federico A, Gravina A, Miranda A, Loguercio C, Romano M. Liver failure in an obese middle-aged woman after biliointestinal bypass. World J Clin Cases. 2013 Apr 16;1(1):52-5.
      50. Barker KB, PalekarNA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol, 2006, vol.101, no.2, pp.368-373.
      51. Jaskiewicz K, Raczynska S, Rzepko R, Sledziński Z. Nonalcoholic fatty liver disease treated by gastroplasty. Dig Dis Sci, 2006, vol.51, no.1, pp.21-26.
      52. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord, 1998, vol.22, no.3, pp.222-226.
      53. Stratopoulos C, Papakonstantinou A, Terzis I, et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005;15(8):1154-1160 57 Jaskiewicz K, Raczynska S, Rzepko R, Sledziński Z. Nonalcoholic fatty liver disease treated by gastroplasty. Dig Dis Sci, 2006, vol.51, no.1, pp.21-26.
      54. Dixon JB, Bhathal PS, O’Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg, 2006, 1vol.6, no.10, pp.1278-1286.
      55. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology, 2009, vol.137, no.2, pp.532-540.
      56. de Almeida SR, Rocha PR, Sanches MD, et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg, 200, vol.16, no.3, pp.270-278.
      57. Speck M., Cho Y. M., Asadi A., Rubino F., Kieffer T. J. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. Am. J. Physiol. Endocrinol. Metab., 2011, vol.300, no.5, pp. 923-932.
      58. Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes, 2013, vol.35, no.5, pp.65-69.
      59. Rabl C, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis, 2012, vol.32, pp.80-91.
      60. Taitano AA, Markow M, Finan JE, Wheeler DE, Gonzalvo JP, Murr MM. Bariatric surgery improves histological features of nonalcoholic Fatty liver disease and liver fibrosis. J Gastrointest Surg, 2015, vol.19, pp.429-437.
      61. Furuya CK Jr, de Oliveira CP, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminaryfindings after 2 years. J Gastroenterol Hepatol, 2007, vol.22, no.4, pp.510-514.
      62. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol, 1995, vol.104, no.1, pp.23-31.
      63. Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obes Surg, 2006, vol.16, no.5, pp.607-611.
      64. LiuX, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg, 2007, vol.17, no.4, pp.486-492.
      65. Keshishian A, Zahriya K, Willes EB. Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months. Obes Surg, 2005, vol.15, no.10, pp.1418-1423.
      66. Kral JG, Thung SN, Brion S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery, 2004, vol.135, no.1, pp.48-58.
      67. Maffazioli GD, Stanford FC, Campoverde Reyes KJ, Stanley TL, Singhal V, Corey KE, Pratt JS, Bredella MA, Misra M. Comparing Outcomes of Two Types of Bariatric Surgery in an Adolescent Obese Population: Roux-en-Y Gastric Bypass vs. Sleeve Gastrectomy. Front Pediatr. 2016 Jul 26, vol.4, no. 78, pp.78-83.
      68. Froylich D, Corcelles R, Daigle C, Boules M, Brethauer S, Schauer P. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis. 2016 Jan, vol.12, no.1, pp.127-131.
      69. Angrisani L., Santonicola A., Iovino P., Formisano G., Buchwald H., Scopinaro N. Bariatric Surgery Worldwide 2013. Obes. Surg., 2015, vol.4, no.3, pp.40-49.
      70. Торопова Я. Г., Корнюшин О. В., Полуничева Е. В. и соавт. Кардиотропные эффекты гастроинтестинальных гормонов у пациентов с метаболическим синдромом после бариатрических операций. Российский физиологический журнал им. И. М. Сеченова, 2016, № 1, С. 100-112.
      71. Корнюшин О. В., Торопова Я. Г., Семикова Г. В. и соавт. Патофизиологические аспекты плейотропных эффектов гастроинтестинальных гормонов. Экспериментальная и клиническая гастроэнтерология, 2016, том134, № 10, С. 4-14.
      72. Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature, 1996, vol.379, pp.69-72.
      73. Tiikkainen M, Bergholm R, Vehkavaara S, Rissanen A, Häkkinen AM, Tamminen M, Teramo K, Yki-Järvinen H. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes, 2003, vol.52, no.12, pp.701-707.
      74. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin, 2009, vol.25, no.8, pp.2401-2411.
      75. Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L, Steinert RE, Heim MH, Beglinger C. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One, 2014, vol.9, no.2 pp. 21-33.
      76. Miyazaki M, Kato M, Tanaka K, Tanaka M, Kohjima M, Nakamura K, Enjoji M, Nakamuta M, Kotoh K, Takayanagi R. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep, 2012, vol.5, no.2, pp.729-733.
      77. Firneisz G, Varga T, Lengyel G, Ghyczy D, Wichmann B, Selmeci L, Tulassay Z, Rбcz K, Somogyi A. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One, 2010, vol.5, no.4, pp.39-52.
      78. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, Garelli P, Casini A, Manco M, Mingrone G, Risaliti A, Frega GN, Benedetti A, Gastaldelli A. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int, 2011, vol.31, no.19, pp.1285-1297.
      79. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology, 2010, vol.51, pp.1584-1592.
      80. D’Alessio DA, Kahn SE, Leusner CR, et al. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest, 1994, vol.93, pp.2263-2266.
      81. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet, 2002, vol.359, pp.824-830.
      82. Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One, vol.2012, no. 7, pp.50-117.
      83. Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther, 2013, vol.37, pp.234-242.
      84. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeu-tic option for hepatic steatosis. Liver Int, 2006, vol.26, pp.1015-1017.
      85. Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One, vol.2012. no.7, pp.56-69.
      86. Armstrong MJ, Barton D, Gaunt P, et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open, 2013, vol.3, pp.39-67.
      87. Armstrong MJ, Hull D, Guo K et al. Glucagon-like peptide 1 decreases lipotoxicity in nonalcoholic steatohepatitis. J Hepatol, 2016 Feb, vol.64, no.2, pp.399-408.
      88. Shirakawa J, Fujii H, Ohnuma K et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes, 2011 Apr, vol.60, no.4, pp.1246-1257.
      89. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance // American Journal of Physiology, 1979, 237(3)
      90. Lee Y-S, Shin S, Shigihara T, et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes, 2007, vol.56, pp.1671-1679.
      91. Zhang L, Yang M, Ren H, et al. GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int, 2013, vol.33, pp.794-804.
      92. Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis, 2010, vol.28, no.1, pp.274-279.
      93. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int, 2011, vol.31, pp.1285-1297.
      94. Sharma S, Mells JE, Fu PP, et al. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One, 2011, vol.6, pp.89-97.
      95. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S. Glucagon-like peptide 1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol, 2011, vol.54, no.6, pp.1214-23.
      96. Kharitonenkov A, Shanafelt AB. FGF21: a novel prospect for the treatment of metabolic diseases. Curr Opin Investig Drugs, 2009, vol.10, pp.359-364.
      97. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes, 2010 Nov, vol.59, no. 11, pp. 2781-9.
      98. Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, Muthupillai R, Chan L, Bajaj M. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia, 2011, vol.54, pp.3093-3100.
      99. Li L, Miao Z, Liu R, Yang M, Liu H, Yang G. Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism. Mol Med, 2011, vol.17, pp.1168-1178.
      100. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology, 2006, vol.43, pp.173-181.
      101. Yamamoto T, Nakade Y, Yamauchi T, Kobayashi Y, Ishii N, Ohashi T, Ito K, Sato K, Fukuzawa Y, Yoneda M. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. World J Gastroenterol, 2016 Feb 28, vol.22, no.8, pp.2512-23.
      102. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, Garelli P, Casini A, Manco M, Mingrone G, Risaliti A, Frega GN, Benedetti A, Gastaldelli A. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int, 2011, vol.31, no.9, pp.1285-1297.
      103. Marchesini G, Pagotto U, Bugianesi E, De Iasio R, Manini R, Vanni E, Pasquali R, Melchionda N, Rizzetto M. Low ghrelin concentrations in nonalcoholic fatty liver disease arerelated to insulin resistance. J Clin Endocrinol Metab, 2003, vol.88, no.12, 5674-9.
      104. Gutierrez-Grobe Y, Villalobos-Blasquez I, Sánchez-Lara K, Villa AR, Ponciano-Rodríguez G, Ramos MH, Chavez-Tapia NC, Uribe M, Méndez-Sánchez N. High ghrelin and obestatin levels and low risk of developing fatty liver. Ann Hepatol, 2010 Jan-Mar, vol.9, no.1, pp.52-7.
      105. Aydin S. Is it appropriate to study blood ghrelin and obestatin in non-alcoholic fatty liver disease (NAFLD) without using protease inhibitors? Ann Hepatol, 2012 Jan-Feb, vol.11, no.1, pp.145-6.
      106. Estep M, Abawi M, Jarrar M, Wang L, Stepanova M, Elariny H, et al. Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes Surg, 2011, vol.21, no.7, pp.1750-7.
      107. Mykhalchyshyn G, Kobyliak N, Bodnar P. Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Metab Disord, 2015 May 19, vol.14, pp.44.
      108. Li Y, Hai J, Li L, Chen X, Peng H, Cao M, Zhang Q. Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development. Endocrine, 2013 Apr, vol.43, no.2, pp.376-86.
      109. Lim CT, Kola B, Grossman A, Korbonits M. The expression of ghrelin O-acyltransferase (GOAT) in human tissues. Endocr J, 2011, vol.58, no.9, pp.707-710.
      110. Nishi Y, Hiejima H, Hosoda H, Kaiya H, Mori K, Fukue Y, Yanase T, Nawata H, Kangawa K, Kojima M. Ingested medium-chain fatty acids are directly utilized for the acyl modification of ghrelin. Endocrinology, 2005, vol.146, no.4, pp.2255-2264.
      111. Zhao TJ, Liang G, Li RL, Xie X, Sleeman MW, Murphy AJ, Valenzuela DM, Yancopoulos GD, Goldstein JL, Brown MS. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci USA, 2010, vol.107, no.3, pp.7467-7472.
      112. Waseem T, Duxbury M, Ito H, Ashley SW, Robinson MK. Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery, 2008, vol.143, no.1, pp.334-342.
      113. Cetin E, Kanbur M, Cetin N, Eraslan G, Atasever A. Hepatoprotective effect of ghrelin on carbon tetrachloride-induced acute liver injury in rats. Regul Pept, 2011, vol.171, pp.1-5.
      114. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med, 2014, vol.370, no.2, pp.2002-2013.
      115. Moretto M, Kupski C, da Silva VD, Padoin AV, Mottin CC. Effect of bariatric surgery on liver fibrosis. Obes Surg, 2011, vol.17, no.2, pp.157-165.
      116. Caiazzo R, Lassailly G, Leteurtre E, Baud G, Verkindt H, Raverdy V, et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg, 2014, vol.260, pp. 893-898.
     


    Full text is published :
    Kornyushin O.V., Toropova Ya.G., Neimark A.E., Glistenkova D.D. et al. MECHANISMS OF INFLUENCE OF BARIATRIC OPERATIONS ON THE COURSE OF NON-ALCOHOLIC FATTY LIVER DISEASE. Experimental and Clinical Gastroenterology Journal. 2017;146(10):61-73
    Read & Download full text

    1. FGBUZ Clinical Hospital No. 122 named after LG Sokolov FMBA of Russia (St. Petersburg, Russian Federation)
    2. Saint-Petersburg state University (St. Petersburg, Russian Federation)
    3. MSH "Road Clinical Hospital of JSC "Russian Railways" (St. Petersburg, Russian Federation)

    Keywords:obscure gastrointestinal bleeding,capsule enteroscopy,ballon-assisted enteroscopy,endoscopic hemostasis

    Abstract:The purpose of this study was the improvement of management results of patients with obscure gastrointestinal bleeding through the development of a differential diagnostic algorithm with the integration of new endoscopic methods. We analyzed the results of diagnosis and treatment of 137 patients with unspecified gastrointestinal bleeding through 8 years. It is revealed, that the subsequent application of capsule and balloon-assisted enteroscopy allows to improve the diagnostic results of diseases caused bleeding, time to establish indications for surgical treatment, to perform the medical benefits of minimal invasive methods (including endoscopic), as well as to avoid “unnecessary” operations in unclear diagnostic situations. In 10 patients the source of bleeding was identified with “traditional” endoscopic technologies without the examination of the small intestine, this underlines the importance of esophagogastroduodenoscopy and colonoscopy of the expert level as a “first step” in diagnosis..

      1. Leighton J. A., Goldstein J., Hirota W. et al. Obscure gastrointestinal bleeding // Gastrointestinal Endoscopy. - 2003. - Vol.58, № 5. - P. 650-651.
      2. Ульянов Д. В., Канарейцева, Т.Д., Ким Д. О. Артериовенозные мальформации желудка как причина рецидивирующих желудочно-кишечных кровотечений // Экспериментальная и клиническая гастроэнтерология. - 2010. - № 11. - С. 107, 109-110.
      3. Bull-Henry K., Al-Kawas F. H. Evaluation of occult gastrointestinal bleeding // American Family Physician. - 2013. - Vol.87, № 6. - P. 430-433.
      4. Воробей А. В., Климович В. В., Карпович Д. И., Жура А. В. Неязвенные гастроинтестинальные кровотечения. Часть I // Хирургия. Журнал им.Н.И Пирогова. - 2009. - № 10. - С. 20, 22.
      5. Barnert J., Messmann H. Diagnosis and management of lower gastrointestinal bleeding // Nature Reviews: Gastroenterology & Hepatology. - 2009. Vol.6. - P. 637-642.
      6. Zuckerman G. R., Prakash H C., Askin M. P., Lewis B. S. AGA Technical Review on the Evaluation and Management of Occult and Obscure Gastrointestinal Bleeding // Gastroenterology. 2000;118:201-221.
      7. Fisher L., Krinsky M. L., Anderson M. A. et al. The role of endoscopy in the management of obscure GI bleeding // Gastrointestinal Endoscopy. - 2010. - Vol.72, № 3. - P. 471.
      8. Pennazio M., Spada C., Eliakim R. et al. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: ESGE Clinical Guideline // Endoscopy. - 2015. - Vol.47, № 4. - P. 355.
      9. Raju G. S., Gerson L., Das A., Lewis B. AGA Institute technical review on obscure gastrointestinal bleeding // Gastroenterology. - 2007. - Vol.133, № 5. - P. 1697-1699.
      10. Melmed G. Y., Lo S. K. Capsule Endoscopy: practical application // Clinical Gastroenterology and Hepatology. - 2005. - Vol. 3, № 5. - P. 411-422.
      11. Домарев Л. В., Старков Ю. Г. Капсульная интестиноскопия. Методика подготовки к исследованию // Российский журнал гастроэнтерологии, гепатологии и колопроктологии. - 2007. - Том 17, № 1. - С. 74-77.
     


    Full text is published :
    Nakatis Ya.A., Kashschenko V.A., Sishkova E.A., Vasyukova E.L. et al. ENDOSCOPIC DIAGNOSIS AND MANAGEMENT OF OBSCURE GASTROINTESTINAL BLEEDING. Experimental and Clinical Gastroenterology Journal. 2017;146(10):74-79
    Read & Download full text

    1. Orenburg State Medical University, Orenburg regional hospital (Orenburg, Russian Federation)

    Keywords:ileocecal transition,bauginia valve,ulcerative colitis,Crohn’s disease

    Abstract:Objective: to improve the diagnosis of diseases of ileocecal transition. Materials and methods. A survey of 191 patients of mature and elderly age, of them men - 63, women - 128. There are 2 groups: 1 - conditionally healthy (97 people) and 2 - patients with ulcerative colitis (76 people) and Crohn’s disease (18 people). Endoscopic studies (videocolonoleoscopy) were carried out with the EVIS EXERA II video system of the CV-180 series, “Olympus” (Japan). Results. It was found that patients with ulcerative colitis and Crohn’s disease significantly more frequently encountered patients with a change in the direction of the caudal flap toward the ascending colon and perpendicular to the cecal axis, a decrease in length and an increase in the thickness of the upper and lower lips of the caudal flap, large sizes of bridles, the formation of a cone-shaped cecum and inflammatory changes in the mucosa of the ileocecal transition. Conclusion. Inflammatory diseases of the ileocecal transition (ulcerative colitis, Crohn’s disease) are accompanied by changes in its elements compared with normal endoscopic anatomy. Knowledge of the norm and the definition of changes that make up the ileocecal transition contribute to the improvement of the diagnosis of inflammatory diseases.

      1. Дронова О. Б. Гастроэзофагеальная рефлюксная болезнь //О.Б.Дронова, И. И. Каган, А. А. Третьяков. - М.: БИНОМ, 2014, - 191 с.
      2. Мирончев А. О. Клиническая анатомия абдоминального отдела пищевода и ее прикладное значение / А.О.Мирончев: Автореф. дис… канд.мед наук. - Оренбург, 2012. - 21с.
      3. Колесникова Е. В. Эндоскопическая анатомия гастродуоденального перехода и ее изменения при язвенной болезни /Е.В.Колесникова: Автореф. дис… канд.мед.наук. - Оренбург, 2017. - 25 с.
      4. Мартынов В. Л. Сфинктерно-клапанные аппараты и рефлюксы пищеварительной системы. /В.Л.Мартынов, А. С. Мухин, В. Н. Рулев. - Н. Новгород: Пламя, 2009. - 151с.
      5. Савин Д. В. Анатомо-экспериментальное обоснование восстановительной микрохирургии илеоцекального клапана при его недостаточности /Автореф. дис… канд.мед.наук. - Оренбург, 2011. - 30 с.
      6. Третьяков А. А. Вариант коррекции илеоцекального клапана при его недостаточности с применением микрохирургической техники /А.А.Третьяков, И. И. Каган, Д. В. Самин, О. Б. Дронова, А. Н. Неверов, С. В. Петров Экспериментальная и клиническая гастроэнтерология № 140 (4), 2017. - с. 79-82
      7. Витебский Я. Д. Основы клапанной гастроэнтерологии //Я.Д.Витебский - Челябинск, 1991. - 304 с.
      8. Адегамова А. М. Рентгеноанатомическая изменчивость ободочной кишки и ее клиническое значение / А.М.Адегамова: Автореф. дис… канд.мед.наук. - Оренбург, 2004. - 28 с.
      9. Колесников Л. Л. Сфинктерология /Л.Л.Колесников. - М.: ГЭОТАР - Медиа, 2008. - 108 с.
      10. Парфенов А. И. Энтерология //А.И.Парфенов. - М.: МИА. 2009-875с.
     


    Full text is published :
    Dronova O.B., Fateev I.N., Petrov S.V., Neverov A.N. COMPARATIVE ANALYSIS OF THE RESULTS OF THE STUDY OF ENDOSCOPIC ANATOMY OF THE ILEOCECAL TRANSITION IN HEALTHY AND DISEASED PATIENTS. Experimental and Clinical Gastroenterology Journal. 2017;146(10):80-82
    Read & Download full text